The therascreen PITX2 RGQ PCR kit with the determined cut-off value of PMR 12 will allow identification of high-risk, lymph node-positive, estrogen-receptor positive, HER2-negative breast cancer patients treated with anthracycline-based chemotherapy with good versus poor outcome. This evidence concerns the gene ESR1 and breast carcinoma.